Clinical Trials Logo

Uterine Corpus Leiomyosarcoma clinical trials

View clinical trials related to Uterine Corpus Leiomyosarcoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01637961 Completed - Clinical trials for Recurrent Uterine Corpus Sarcoma

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Start date: August 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well alisertib works in treating patients with leiomyosarcoma of the uterus that has come back or persistent. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01220609 Completed - Clinical trials for Recurrent Uterine Corpus Sarcoma

Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well ixabepilone works in treating patients with recurrent or persistent leiomyosarcoma of the uterus previously treated with chemotherapy. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

NCT ID: NCT00897442 Completed - Melanoma Clinical Trials

Collecting Tumor Samples From Patients With Gynecological Tumors

Start date: June 1992
Phase: N/A
Study type: Observational

This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in the study of cancer.

NCT ID: NCT00031629 Completed - Clinical trials for Recurrent Uterine Corpus Sarcoma

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Start date: January 2005
Phase: Phase 2
Study type: Interventional

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim or pegfilgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. This phase II trial is studying how well combination chemotherapy plus filgrastim or pegfilgrastim works in treating patients with recurrent or persistent cancer of the uterus.

NCT ID: NCT00025220 Completed - Clinical trials for Recurrent Uterine Corpus Sarcoma

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Start date: September 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.